14.3% rate (😮) of a tumor in those presenting with periappendiceal abscess. 52 of the 53 patients with tumors were over age 35. Don’t skip out on the interval appy for adult patients with appendicitis! 🔪🔪🔪

It was a happy task, being asked to reflect on the contributions of the Branch. Humbly standing on the shoulders of giants, creating the medicines of tomorrow. TIL immunotherapy comes of age: a journey of development in the Surgery Branch, NCI jitc.bmj.com/content/13/4/e…

Can anyone complete the phrase? Share an image of your APPs. We are fortunate to have such a great group of inpatient APPs for GI Surgonc Moffitt Cancer Center ! Daniel Anaya Dr. Patrick Hwu Physician Assistants Michael Lidsky, MD, FACS Mike Wach MD Stepheny Berry, MD, FACS Genevieve Boland, MD, PhD Melissa Hogg Flavio G Rocha, MD, FACS, FSSO

Absolutely ecstatic to match such a talented group of surgeons to Moffitt Cancer Center! Looking forward to many hours of CRS/HIPEC with all of you 🔪🔥

The work of 200+ experts in peritoneal surface malignancies: Guidelines for the management of patients with Colorectal Peritoneal Metastases 🩺🩻🧑🏻‍⚕️ So proud to be a part of this!

Excited to share our work summarizing the existing guidelines (Chicago Consensus, PSOGI, NCCN, and the brand new Yale PSM group) for current management of patients with Colorectal Peritoneal Metastases! Society of Surgical Oncology Annals of Surgical Oncology COLONTOWN Moffitt Cancer Center link.springer.com/article/10.124…

#AudioVisualAbstract : Impact of PIPAC-Oxaliplatin on Functional Recovery, Good Days, and Survival in a Refractory #Colorectal and #Appendiceal #Carcinomatosis : Secondary Analysis of the US PIPAC Collaborative Phase 1 Trial M. Talha Waheed rdcu.be/euuGd Syed A. Ahmad

Featured: National Guidelines for Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy ( #HIPEC ) in #PeritonealMalignancies : A Worldwide Systematic Review and Recommendations of Strength Analysis. ow.ly/BGvb50Wojqr Kurt Schultz Syed A. Ahmad

The 5th annual Moffitt Hepatobiliary Complex Surgery Course Moffitt Cancer Center is underway! A big welcome to the CGSO fellows and guest faculty Dr. Katz, Dr. Warner, and Dr. Vera. #HPB #SurgOnc #academicsurgery

“Medical professionals can no longer fully trust federal health guidance, and our patients are the ones who will suffer the most.” Excellent read from Danielle Ofri on the reality for clinicians as NIH, CDC, FDA recs are put under political controls. nytimes.com/2025/07/28/opi…

x.com/i/article/1950…

Appendix cancer is rare, but cases are rising, especially among younger generations. For years, Tatiana’s symptoms were dismissed as something minor. But a routine hernia surgery revealed the unexpected: appendix cancer that had silently spread. Her message now? Listen to your

The X-less Sean Dineen is an expert leader of the Peritoneal Surface Malignancy program at Moffitt Cancer Center He and Mike Wach MD take outstanding care of patients with their multidisciplinary team. Honored to work with him for our #CGSO fellows. Society of Surgical Oncology

Very excited to be included in #FollowFriday and love helping my patients Moffitt Cancer Center !

There's still time to secure your spot for this week's webinar! Join us to explore treatment strategies for colorectal and appendiceal cancers—including systemic therapy, cytoreductive surgery, and HIPEC. Register before it's too late: ow.ly/MGvs50WnJ2X

Today ends Appendix Cancer Awareness Month. As a surgical oncologist Moffitt Cancer Center, I treat rare cancers like appendix cancer and Pseudomyxoma Peritonei (PMP). Specialized centers and treatments like cytoreductive surgery with HIPEC lead to the best outcomes. Appendix Cancer PMP Research Foundation

Registration is officially open for ACT 2026! Join us in Fort Lauderdale, FL as we celebrate the 20th Anniversary of this meeting. Secure your spot: ow.ly/vslY50WT9xq

NICHE-2 absolutely delivers. Game over for chemo in dMMR colon cancer 💥🧬 In locally advanced dMMR colon cancer, FOxTROT already showed us chemo doesn’t work, and now NICHE-2 makes it undeniable. 💊 Neoadjuvant nivolumab + ipilimumab → • 99% pathologic response • 67%

Honored to announce that I’ll be participating in an incredible program with Society of Surgical Oncology over the upcoming year! Very grateful to be paired with a senior surgeon to mentor me in clinical trials, PSM, and success as a surgical oncologist. Moffitt Cancer Center #SSO2026

Increased surgeon physiological stress during the first 5 minutes of surgery was associated with reduced odds of major surgical complications. Optimizing surgeon stress may provide an opportunity to improve surgical performance and patient outcomes. 🔗 ja.ma/3JKxCSm